natgillin/translations-raw huggingface dataset:
Molecular interactions occur between corticosteroids and LABAs, whereby steroids activate the beta2receptor gene, increasing receptor number and sensitivity and LABAs prime the glucocorticoid receptor for steroid-dependent activation and enhance cell nuclear translocation.
Med kortikosteroidi in LABA prihaja do molekulskih medsebojnih delovanj, pri čemer steroidi aktivirajo gen za beta2-receptor ter povečajo število in občutljivost receptorjev, LABA pa pripravijo glukokortikoidne receptorje na aktiviranje s steroidi in povečajo celično jedrno translokacijo.
Component of a multipack, can't be sold separately.
Sestavina pakiranja z več inhalatorji, ni za ločeno prodajo.
If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Če se pri bolniku pojavijo simptomi, kot so zamegljen vid ali druge motnje vida, ga je potrebno upoštevati za napotitev k oftalmologu zaradi ovrednotenja možnih vzrokov, ki lahko vključujejo katarakto, glavkom ali redke bolezni, kot je centralna serozna horioretinopatija, o katerih so poročali po sistemski in topični uporabi kortikosteroidov.
Allergen challenge study
Študija provokacije z alergenom
The primary endpoint was all-cause mortality and a secondary endpoint was a composite of cardiovascular events (on-treatment cardiovascular death, myocardial infarction, stroke, unstable angina, or transient ischemic attack).
Primarni opazovani dogodek je bila umrljivost zaradi vseh vzrokov, sekundarni opazovani dogodek pa so sestavljali kardiovaskularni dogodki (kardiovaskularna smrt med zdravljenjem, miokardni infarkt, možganska kap, nestabilna angina pektoris ali tranzitorna ishemična ataka).
After inhalation, patients should rinse their mouth with water without swallowing.
Po inhalaciji morajo bolniki splakniti usta z vodo, vode ne smejo pogoltniti.
In vitro plasma protein binding in human plasma of fluticasone furoate and vilanterol was high, on average >99.6% and 93.9%, respectively.
Vezava na plazemske beljakovine v človeški plazmi in vitro je bila visoka: flutikazonfuroata v povprečju > 99,6 % in vilanterola v povprečju
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity.
Flutikazonfuroat je sintetičen trifluoriran kortikosteroid z močnim protivnetnim delovanjem.
During clinical studies, pneumonia and fractures were more frequently commonly observed in patients with COPD.
Med kliničnimi študijami so pljučnico in zlome pogosteje zabeležili pri bolnikih s KOPB.
When you first use the Ellipta inhaler you do not need to check that it is working properly, and you do not need to prepare it for use in any special way.
Ko prvič uporabite inhalator Ellipta, vam ni treba preverjati, ali deluje pravilno in vam ga tudi ni treba posebej pripravljati za uporabo.
It will only be effective as long as you are using it. Do not stop unless your doctor advises you to, even if you feel better.
Ne nehajte ga uporabljati, če vam tega ne svetuje zdravnik, tudi če se počutite bolje.
If you become wheezy or breathless, or develop any other symptoms of an asthma attack, use your quick-acting inhaler (e.g. salbutamol), then seek medical advice.
Če se vam pojavi piskajoče dihanje ali zasoplost ali kakšni drugi simptomi napada astme, uporabite svoj hitrodelujoči inhalator (npr. salbutamol) in nato poiščite zdravniški nasvet.
P value (95% CI)
Vrednost p (95 % IZ)
• pain and irritation in the back of the mouth and throat
• bolečine in draženje v zadnjem delu ust in v žrelu,
Multipack: 90 (3 packs of 30) doses
Pakiranje z več inhalatorji: 90 (3 pakiranja po 30) odmerkov
Keep the inhaler inside the sealed tray to protect from moisture and only remove immediately before first use.
Inhalator hranite v zaprti embalaži za zaščito pred vlago in ga odprite tik pred prvo uporabo.
HZC112206 and HZC112207 were 24 week randomised, double-blind, placebo controlled, parallel group studies comparing the effect of the combination to vilanterol and FF alone and placebo.
Študiji HZC112206 in HZC112207 sta bili 24-tedenski randomizirani, dvojno slepi, s placebom kontrolirani študiji vzporednih skupin, ki sta primerjali vpliv kombinacije z vplivi vilanterola in FF samih ter placeba.
The lost dose will be securely held inside the inhaler, but it will no longer be available to be inhaled.
Izgubljeni odmerek bo varno shranjen v inhalatorju, vendar ne bo več na voljo za inhalacijo.
• high temperature (fever)
• zvišana telesna temperatura (vročina),
Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures.
Kardioselektivna blokada beta pride v poštev le pri zelo izrazitih učinkih prevelikega odmerjanja vilanterola, ki so klinično zaskrbljujoči in se ne odzivajo na podporne ukrepe.
14 doses 30 doses
14 odmerkov 30 odmerkov
- Contact your doctor if you experience increased thirst, frequent urination or unexplained tiredness
- Posvetujte se s svojim zdravnikom, če se vam pojavi povečana žeja, pogosto uriniranje ali nepojasnjena utrujenost (znaki povišanega sladkorja v krvi).
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 14 doses
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 14 odmerkov
You may not be able to taste or feel the medicine, even when you are using the inhaler correctly.
Zdravila morda ne boste ne okusili, ne občutili, tudi če inhalator uporabljate pravilno.
This will make it less likely that you will develop a sore mouth or throat as side effects.
Tako bo manj verjetno, da se vam kot neželen učinek pojavi vnetje ust ali žrela.
Visual disturbance
Motnje vida
Animal studies showed no effect of fluticasone furoate/vilanterol trifenatate on fertility (see section 5.3).
Študije na živalih niso pokazale, da bi flutikazonfuroat/vilanterol vplival na plodnost (glejte poglavje 5.3).
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal products subject to medical prescription.
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept.
Pneumonia in patients with asthma
Pljučnica pri bolnikih z astmo
The inhaler is a multi-component device composed of polypropylene, high density polyethylene, polyoxymethylene, polybutylene terephthalate, acrylonitrile butadiene styrene, polycarbonate and stainless steel.
Inhalator je večdelni pripomoček, izdelan iz polipropilena, polietilena velike gostote, polioksimetilena, polibutilentereftalata, akrilonitril butadienstirena, polikarbonata in nerjavečega jekla.
The 184/22 micrograms strength is used to treat asthma in adults and adolescents aged 12 years and older.
Jakost 184/22 mikrogramov se uporablja za zdravljenje astme pri odraslih in mladostnikih, starih 12 let in več.
• Remove the inhaler from your mouth.
• Inhalator naj vzame iz ust.
The safety and efficacy of Relvar Ellipta in children under 12 years of age has not yet been established in the indication for asthma.
Varnost in učinkovitost zdravila Relvar Ellipta pri otrocih, mlajših od 12 let, za indikacijo astme še nista ugotovljeni.
All-cause mortality was: fluticasone furoate/vilanterol, 6.0%; placebo, 6.7%; fluticasone furoate, 6.1%; vilanterol, 6.4%.
Umrljivost zaradi vseh vzrokov je bila med uporabo flutikazonfuroata/vilanterola 6,0 %, placeba 6,7 %, flutikazonfuroata 6,1 % in vilanterola 6,4 %.
Do not use this medicine after the expiry date which is stated on the pack after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pakiranju poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Fluticasone furoate was not teratogenic in rats or rabbits, but delayed development in rats and caused abortion in rabbits at maternally toxic doses.
Flutikazonfuroat pri podganah in kuncih ni bil teratogen, a je pri podganah upočasnil razvoj, pri kuncih pa je v maternalnih toksičnih odmerkih povzročil splave.
Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.
Če bolnikova uporaba kratkodelujočih bronhodilatatorjev za olajšanje narašča, to kaže na slabšanje urejenosti bolezni in bolnikovo stanje je treba znova oceniti.
In genetic toxicity studies, vilanterol (as alpha-phenylcinnamate) and triphenylacetic acid were not genotoxic indicating that vilanterol (as trifenatate) does not represent a genotoxic hazard to humans.
Vilanterolijev trifenatat Študije genotoksičnosti kažejo, da vilanterol (v obliki alfa-fenilcinamata) in trifenilocetna kislina nista genotoksična, to kaže, da vilanterol (v obliki trifenatata) za človeka ne pomeni genotoksične nevarnosti.
Chronic obstructive pulmonary disease (COPD) is a serious, long term lung disease where the airways become inflamed and thickened.
Kronična obstruktivna pljučna bolezen (KOPB) je resna, kronična pljučna bolezen, kjer se dihalne poti vnamejo in zadebelijo.
All subjects were using an ICS (Inhaled corticosteroid) with or without LABA for at least 12 weeks prior to visit 1.
Vsi preiskovanci so vsaj 12 tednov pred 1. obiskom uporabljali inhalirani kortikosteroid (ICS) z LABA ali brez njega.
The MAH shall perform the required Pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
There have been reports of increases in blood glucose levels in diabetic patients and this should be considered when prescribing to patients with a history of diabetes mellitus.
Opisani so primeri zvišane koncentracije glukoze v krvi pri sladkornih bolnikih; to morate upoštevati, če zdravilo predpišete bolnikom z anamnezo sladkorne bolezni.
Caution is advised when co-administering with strong CYP 3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicistat-containing products) as there is potential for increased systemic exposure to both fluticasone furoate and vilanterol.
Previdnost je potrebna med sočasno uporabo z močnimi zaviralci CYP3A4 (npr. ketokonazol, ritonavir, zdravila, ki vsebujejo kobicistat), ker obstaja možnost večje sistemske izpostavljenosti flutikazonfuroatu in vilanterolu.
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
Zdravilo Relvar Ellipta je indicirano za simptomatsko zdravljenje odraslih s KOPB, ki imajo FEV1 < 70 % predvidenega normalnega (po bronhodilatatorju), z anamnezo poslabšanj kljub rednemu zdravljenju z bronhodilatatorjem.
The step-by-step instructions shown below for the 30-dose Ellipta inhaler (30 day supply) also apply to the 14-dose Ellipta inhaler (14 day supply).
Spodnja navodila za inhalator Ellipta s 30 odmerki (30-dnevna zaloga) veljajo tudi za inhalator Ellipta s 14 odmerki (14-dnevna zaloga).
However, the patient should be informed that regular daily usage is necessary to maintain control of asthma symptoms and that use should be continued even when asymptomatic.
Vendar je treba bolnikom povedati, da je za vzdrževanje nadzora nad simptomi astme potrebna redna vsakodnevna uporaba in da morajo zdravilo uporabljati tudi, ko nimajo simptomov.
Oral corticosteroids and antibiotics were allowed for the acute treatment of COPD exacerbations with specific guidelines for use.
Za akutno zdravljenje poslabšanj KOPB je bila dovoljena uporaba peroralnih kortikosteroidov in antibiotikov s specifičnimi smernicami za njihovo uporabo.
There is no specific treatment for an overdose with fluticasone furoate/vilanterol.
Specifičnega zdravljenja za preveliko odmerjanje flutikazonfuroata/vilanterola ni.
Just follow these step-by-step instructions.
Samo upoštevajte spodnja navodila.
Fluticasone furoate and vilanterol are substrates for P-glycoprotein (P-gp), however, concomitant administration of fluticasone furoate/vilanterol with P-gp inhibitors is considered unlikely to alter fluticasone furoate or vilanterol systemic exposure since they are both well absorbed molecules.
Flutikazonfuroat in vilanterol sta substrata P-glikoproteina (P-gp), vendar ni verjetno, da bi sočasna uporaba flutikazonfuroata/vilanterola z zaviralci P-gp spremenila sistemsko izpostavljenost flutikazonfuroata ali vilanterola, ker se obe molekuli dobro absorbirata.
Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
Med možnimi sistemskimi učinki so Cushingov sindrom, Cushingoidne značilnosti, supresija nadledvičnih žlez, zmanjšanje mineralne gostote kosti, upočasnitev rasti pri otrocih in mladostnikih, katarakta in glavkom ter, redkeje, različni psihološki ali vedenjski učinki, med njimi psihomotorična hiperaktivnost, motnje spanja,
However, other corticosteroids and beta2-agonists are detected in human milk (see section 5.3).
Se pa v materinem mleku pri človeku pojavijo drugi kortikosteroidi in agonisti adrenergičnih receptorjev beta2 (glejte poglavje 5.3).
In an integrated analysis of both studies, fluticasone furoate/vilanterol 92/22 micrograms showed clinically meaningful improvements in lung function.
V integrirani analizi obeh študij je flutikazonfuroat/vilanterol 92/22 mikrogramov pokazal klinično pomembno izboljšanje pljučne funkcije.
Given this low oral bioavailability, systemic exposure for fluticasone furoate and vilanterol following inhaled administration is primarily due to absorption of the inhaled portion of the dose delivered to the lung.
Glede na majhno peroralno biološko uporabnost je sistemska izpostavljenost flutikazonfuroatu in vilanterolu po inhaliranju v prvi vrsti posledica absorpcije inhaliranega dela odmerka, ki pride v pljuča.
What Relvar Ellipta is and what it is used for 2.
Kaj je zdravilo Relvar Ellipta in za kaj ga uporabljamo 2.
What you need to know before you use Relvar Ellipta 3.
Kaj morate vedeti, preden boste uporabili zdravilo Relvar Ellipta 3.
The increase in vilanterol exposure was not associated with an increase in beta2-agonist related systemic effects on heart rate, blood potassium or QTcF interval.
Večje izpostavljenosti vilanterolu ni spremljalo povečanje z agonistom adrenergičnih receptorjev beta2 povezanih sistemskih učinkov na srčno frekvenco, raven kalija v krvi ali interval QTcF.
Overall, across the two studies combined 2009 (62%) patients had cardiovascular history/risk factors at screening.
V celoti je imelo ob presejanju kardiovaskularno anamnezo/dejavnike tveganja v obeh študijah skupaj 2009 (62 %) bolnikov.
In two replicate 12 month studies in a total of 3,255 patients with COPD the incidence of bone fractures overall was low in all treatment groups, with a higher incidence in all Relvar Ellipta groups (2%) compared with the vilanterol 22 micrograms group (<1%).
V dveh repliciranih 12-mesečnih študijah pri skupno 3.255 bolnikih s KOPB je bila celotna incidenca zlomov kosti majhna v vseh terapevtskih skupinah, a je bila večja v vseh skupinah z zdravilom Relvar Ellipta (2 %) kot v skupini s 22 mikrogrami vilanterola (< 1 %).
Vilanterol is primarily metabolised by O-dealkylation to a range of metabolites with significantly reduced 1- and 2-agonist activity.
Vilanterol se presnovi predvsem z O-dealkilacijo v celo vrsto presnovkov, ki imajo bistveno manjše β1 in β2 agonistično delovanje.
Although there were more fractures in the Relvar Ellipta groups compared with the vilanterol 22 micrograms group, fractures typically associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in <1% of the Relvar Ellipta and vilanterol treatment arms.
Čeprav je bilo v skupinah z zdravilom Relvar Ellipta več zlomov kot v skupini z 22 mikrogrami vilanterola, so se zlomi, ki so tipično povezani z uporabo kortikosteroidov (npr. spinalna kompresija/torakolumbalni zlomi vretenc, zlomi kolka in acetabula), tako v krakih z zdravilom Relvar Ellipta kot z vilanterolom pojavili pri < 1 %.
The apparent plasma elimination half-life of vilanterol following single inhaled administration of fluticasone furoate/vilanterol was, on average, 2.5 hours.
Navidezni plazemski eliminacijski razpolovni čas vilanterola po enkratni inhalacijski uporabi kombinacije flutikazonfuroat/vilanterol je bil v povprečju 2,5 ure.
Do not block the air-vents with your fingers.
Pazite, da ne boste s prsti prekrili rež za zrak.
if you think the above applies to you, don't use Relvar Ellipta until you have checked with your doctor.
Če menite, da to velja za vas, ne uporabite zdravila Relvar Ellipta, dokler se ne posvetujete s svojim zdravnikom.
Do not open until ready to inhale.
Ne odpirajte, dokler niste pripravljeni na inhaliranje.
Don't use this medicine if you are breastfeeding unless your doctor tells you that you can.
Ne uporabite tega zdravila, če dojite, razen če vam je vaš zdravnik rekel, da ga lahko.
Fluticasone furoate is primarily metabolised through hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity.
Flutikazonfuroat se presnovi predvsem s hidrolizo S-fluorometilkarbotioatne skupine v presnovke, ki imajo bistveno manjše kortikosteroidno delovanje.
Patients usually experience an improvement in lung function within 16-17 minutes of inhaling Relvar Ellipta.
Bolnikom se pljučna funkcija po navadi izboljša v 16 do 17 minutah po inhaliranju zdravila Relvar Ellipta.
For an elderly subject (aged 84 years) with low bodyweight (35 kg) vilanterol AUC (0-24) is predicted to be 35% higher than the population estimate (subject with COPD aged 60 years and bodyweight of 70 kg), whilst Cmax was unchanged.
(starost 84 let) z majhno telesno maso (35 kg) je predvideni AUC(0-24) vilanterola 35 % višji od populacijske ocene (bolnik s KOPB, star 60 let in s telesno maso 70 kg), Cmax pa se ni spremenila.
long-acting beta2-adrenergic agonists, such as salmeterol
- dolgodelujoči agonisti adrenergičnih receptorjev beta2, kot npr. salmeterol.
The effective half-life for accumulation of vilanterol, as determined from inhalation administration of repeat doses of vilanterol 25 micrograms, is 16.0 hours in subjects with asthma and 21.3 hours in subjects with COPD.
Efektivni razpolovni čas za kopičenje vilanterola, določen z inhalacijsko uporabo ponavljajočih se odmerkov 25 mikrogramov vilanterola, je pri osebah z astmo 16,0 ur in pri osebah s KOPB 21,3 ure.
Prior to randomization, subjects were required to discontinue previous COPD medications used at baseline, which included long-acting bronchodilators plus inhaled corticosteroids (28%), long-acting bronchodilators alone (11%) and inhaled corticosteroids alone (4%).
Pred randomizacijo so morali bolniki prenehati uporabljati predhodna zdravila za KOPB, ki so jih jemali do izhodišča; to je vključevalo dolgodelujoče bronhodilatatorje in inhalirane glukokortikoide (28 %), dolgodelujoče bronhodilatatorje same (11 %) in inhalirane glukokortikoide same (4 %).
When you take the inhaler out of its tray, it will be in the ‘closed' position.
Ko vzamete inhalator iz embalaže, bo v položaju "zaprto".
If symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief.
Če se simptomi pojavijo v obdobju med odmerki, mora bolnik za takojšnje olajšanje uporabiti inhalirani kratkodelujoči agonist adrenergičnih receptorjev beta2.
184 micrograms [n=194]) both administered once daily compared with FP 500 micrograms twice daily [n=195].
[n = 197] in 184 mikrogramov FF [n = 194], obeh uporabljenih enkrat na dan, v primerjavi s FP 500 mikrogramov dvakrat na dan [n = 195].
Fluticasone furoate/vilanterol should not be used to treat acute asthma symptoms or an acute exacerbation in COPD, for which a short-acting bronchodilator is required.
Flutikazonfuroat/vilanterol se ne sme uporabljati za zdravljenje simptomov akutne astme ali akutnega poslabšanja KOPB; za to je potreben kratkodelujoč bronhodilatator.
Prescribers should be aware that in patients with asthma, fluticasone furoate (FF) 100 micrograms once daily is approximately equivalent to fluticasone propionate (FP) 250 micrograms twice daily, while FF 200 micrograms once daily is approximately equivalent to FP 500 micrograms twice daily.
Zdravniki, ki predpisujejo to zdravilo, morajo vedeti, da je pri bolnikih z astmo odmerek 100 mikrogramov flutikazonfuroata (FF) enkrat na dan približno enakovreden odmerku 250 mikrogramov flutikazonpropionata (FP) dvakrat na dan, odmerek 200 mikrogramov FF enkrat na dan pa je približno enakovreden odmerku 500 mikrogramov FP dvakrat na dan.
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods.
Med uporabo vseh inhalacijskih kortikosteroidov se lahko pojavijo sistemski učinki, zlasti med dolgotrajno uporabo velikih odmerkov.
The increase in fluticasone furoate exposure was associated with a 27% reduction in 0-24 hours weighted mean serum cortisol.
Povečanje izpostavljenosti flutikazonfuroatu je spremljalo 27 % zmanjšanje utežene povprečne koncentracije kortizola v obdobju 0-24 ur.
Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol.
Zdravilo Relvar Ellipta vsebuje dve zdravilni učinkovini: flutikazonfuroat in vilanterol.
Fluticasone furoate and vilanterol represent two classes of medications (a synthetic corticosteroid and a selective, long-acting beta2-receptor agonist).
Flutikazonfuroat in vilanterol predstavljata dve skupini zdravil (sintetičen kortikosteroid in selektiven, dolgodelujoč agonist adrenergičnih receptorjev beta2).
Serial FEV1 measurements were compared with pre-allergen challenge values taken after saline inhalation (baseline).
Zaporedne meritve FEV1 so primerjali z vrednostmi pred provokacijo z alergenom, dobljene po inhaliranju fiziološke raztopine (izhodišče).
It may not be possible to taste or feel the medicine, even when using the inhaler correctly.
Zdravila se morda ne bo ne okusilo, ne občutilo, tudi če se inhalator uporablja pravilno.
In the 12 months prior to the study, 61% of subjects reported no COPD exacerbations and 39% of subjects reported ≥1 moderate/severe COPD exacerbation.
V 12 mesecih pred študijo je imelo poslabšanje KOPB 61 % bolnikov, 39 % pa jih je imelo ≥ 1 zmerno/hudo poslabšanje
Fluticasone furoate or vilanterol has no or negligible influence on the ability to drive and use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Flutikazonfuroat in vilanterol nimata vpliva ali imata zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
For patients with moderate or severe hepatic impairment the maximum dose is 92/22 micrograms (see section 4.4).
Za bolnike z zmerno ali hudo okvaro jeter je najvišji odmerek 92/22 mikrogramov (glejte poglavje 4.4).
The pharmacologic effects of beta2-adrenoceptor agonist active substances, including vilanterol trifenatate, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP).
Farmakološke učinke agonistov adrenergičnih receptorjev beta2, vključno z vilanterolijevim trifenatatom, je mogoče vsaj deloma pripisati stimulaciji znotrajcelične adenilat-ciklaze, tj. encima, ki katalizira pretvorbo adenozin trifosfata (ATP) v ciklični 3', 5'-adenozin monofosfat (ciklični AMP).
Relvar Ellipta is for inhalation use only.
Zdravilo Relvar Ellipta je namenjeno samo za inhalacijsko uporabo.
Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough.
Simptomi se pojavljajo in izginjajo; med njimi so kratka sapa, piskajoče dihanje, tiščanje v prsih in kašelj.